Sistema de Salut de Catalunya
Institut Català de la Salut
[Mitsikostas DDD] Neurology Department, Aeginition Hospital, Medical School, National & Kapodistrian University of Athens, Athens, Greece. [Caronna E, Pozo-Rosich P] Unitat de Cefalees, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Cefalea i Dolor Neurològic, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [De Tommaso M] Neurophysiopathology Unit, DiBrain Department, Aldo Moro University, Bari, Italy. [Deligianni CI] Athens Naval Hospital, Athens, Greece. [Ekizoglu E] Department of Neurology, Faculty of Medicine, Istanbul University, Istanbul, Istanbul, Turkey. [Bolay H] Department of Neurology and Algology, NÖROM, Gazi University Ankara, Ankara, Turkey
Vall d'Hebron Barcelona Hospital Campus
2024-05-22T06:48:53Z
2024-05-22T06:48:53Z
2024-06
Chronic daily headache; Headache; Neurological disorders
Cefalea crònica diària; Mal de cap; Trastorns neurològics
Cefalea crónica diaria; Dolor de cabeza; Trastornos neurológicos
Background and purpose The aim was to provide insights to the characteristics of headache in the context of COVID-19 on behalf of the Headache Scientific Panel and the Neuro-COVID-19 Task Force of the European Academy of Neurology (EAN) and the European Headache Federation (EHF). Methods Following the Delphi method the Task Force identified six relevant questions and then conducted a systematic literature review to provide evidence-based answers and suggest specific diagnostic criteria. Results No data for facial pain were identified in the literature search. (1) Headache incidence during acute COVID-19 varies considerably, with higher prevalence rates in prospective compared to retrospective studies (28.9%–74.6% vs. 6.5%–34.0%). (2) Acute COVID-19 headache is usually bilateral or holocranial and often moderate to severe with throbbing pain quality lasting 2–14 days after first signs of COVID-19; photo-phonophobia, nausea, anosmia and ageusia are common associated features; persistent headache shares similar clinical characteristics. (3) Acute COVID-19 headache is presumably caused by immune-mediated mechanisms that activate the trigeminovascular system. (4) Headache occurs in 13.3%–76.9% following SARS-CoV-2 vaccination and occurs more often amongst women with a pre-existing primary headache; the risk of developing headache is higher with the adenoviral-vector-type vaccines than with other preparations. (5) Headache related to SARS-CoV-2 vaccination is mostly bilateral, and throbbing, pressing, jolting or stabbing. (6) No studies have been conducted investigating the underlying mechanism of headache attributed to SARS-CoV-2 vaccines. Conclusion The results of this joint EAN/EHF initiative provide a framework for a better understanding of headache in the context of SARS-CoV-2 infection and vaccination.
Article
Published version
English
COVID-19 (Malaltia) - Vacunació; Medicaments - Efectes secundaris; Cefalàlgia - Epidemiologia; Dolor facial - Epidemiologia; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination; Other subheadings::Other subheadings::Other subheadings::/adverse effects; DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Neurologic Manifestations::Pain::Headache; DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Neurologic Manifestations::Pain::Facial Pain; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación; Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos; ENFERMEDADES::afecciones patológicas, signos y síntomas::signos y síntomas::manifestaciones neurológicas::dolor::cefalea; ENFERMEDADES::afecciones patológicas, signos y síntomas::signos y síntomas::manifestaciones neurológicas::dolor::dolor facial
Wiley Open Access
European Journal of Neurology;31(6)
https://doi.org/10.1111/ene.16251
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1655]
